

Tawanda Gumbo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1241212/publications.pdf>

Version: 2024-02-01

168
papers

8,678
citations

41258

49
h-index

53109

85
g-index

170
all docs

170
docs citations

170
times ranked

5699
citing authors

#	ARTICLE	IF	CITATIONS
1	Antimicrobial Resistance: Pharmacokinetics&Pharmacodynamics of Antimicrobial Therapy: It&TM's Not Just for Mice Anymore. <i>Clinical Infectious Diseases</i> , 2007, 44, 79-86.	2.9	623
2	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> ,the, 2017, 5, 291-360.	5.2	459
3	Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes. <i>Journal of Infectious Diseases</i> , 2013, 208, 1464-1473.	1.9	378
4	Concentration-Dependent <i>Mycobacterium tuberculosis</i> Killing and Prevention of Resistance by Rifampin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3781-3788.	1.4	314
5	Selection of a Moxifloxacin Dose That Suppresses Drug Resistance in <i>Mycobacterium tuberculosis</i> , by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling. <i>Journal of Infectious Diseases</i> , 2004, 190, 1642-1651.	1.9	309
6	Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability. <i>Journal of Infectious Diseases</i> , 2011, 204, 1951-1959.	1.9	246
7	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. <i>Lancet Respiratory Medicine</i> ,the, 2014, 2, 321-338.	5.2	237
8	Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy. <i>Clinical Infectious Diseases</i> , 2012, 55, 169-177.	2.9	199
9	Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3197-3204.	1.4	178
10	The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4806-4815.	1.4	158
11	Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 5058-5068.	1.4	154
12	Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2329-2336.	1.4	149
13	Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1208-1219.	2.5	130
14	New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1484-1491.	1.4	126
15	Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 38-45.	1.4	123
16	Efflux&Pump&Derived Multiple Drug Resistance to Ethambutol Monotherapy in <i>Mycobacterium tuberculosis</i> and the Pharmacokinetics and Pharmacodynamics of Ethambutol. <i>Journal of Infectious Diseases</i> , 2010, 201, 1225-1231.	1.9	119
17	A Meta-Analysis of Self-Administered vs Directly Observed Therapy Effect on Microbiologic Failure, Relapse, and Acquired Drug Resistance in Tuberculosis Patients. <i>Clinical Infectious Diseases</i> , 2013, 57, 21-31.	2.9	111
18	Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. <i>Lancet Respiratory Medicine</i> ,the, 2017, 5, 269-281.	5.2	106

#	ARTICLE	IF	CITATIONS
19	An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 24-34.	1.4	105
20	Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 968-974.	1.4	102
21	Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. <i>Clinical Infectious Diseases</i> , 2016, 63, S63-S74.	2.9	102
22	Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3714-3719.	1.4	99
23	Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	99
24	Isoniazidâ€™s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion of Mycobacterium tuberculosis in the Log Phase of Growth. <i>Journal of Infectious Diseases</i> , 2007, 195, 194-201.	1.9	93
25	Pharmacokinetic-Pharmacodynamic and Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for Industry and Academia. <i>Journal of Infectious Diseases</i> , 2015, 211, S96-S106.	1.9	93
26	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	5.2	92
27	Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. <i>Nature Medicine</i> , 2020, 26, 529-534.	15.2	87
28	Candida glabrata Fungemia Clinical Features of 139 Patients. <i>Medicine (United States)</i> , 1999, 78, 220-227.	0.4	81
29	Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	81
30	Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes. <i>Clinical Infectious Diseases</i> , 2015, 61, S25-S31.	2.9	79
31	Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis. <i>Journal of Infectious Diseases</i> , 2015, 211, S83-S95.	1.9	79
32	A new evolutionary and pharmacokineticâ€™ pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. <i>Current Opinion in Pharmacology</i> , 2011, 11, 457-463.	1.7	76
33	Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S293-S302.	2.9	74
34	Pharmacodynamic Evidence that Ciprofloxacin Failure against Tuberculosis Is Not Due to Poor Microbial Kill but to Rapid Emergence of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3178-3181.	1.4	73
35	Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3695-3700.	1.4	69
36	Population pharmacokinetics of micafungin in adult patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 329-331.	0.8	69

#	ARTICLE	IF	CITATIONS
37	Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances. <i>Pharmacotherapy</i> , 2009, 29, 1468-1481.	1.2	65
38	Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6337-6343.	1.4	63
39	Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2847-2854.	1.4	61
40	Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm. <i>Clinical Infectious Diseases</i> , 2015, 61, S18-S24.	2.9	61
41	Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments. <i>Clinical Infectious Diseases</i> , 2015, 61, S10-S17.	2.9	60
42	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1774-1780.	2.9	59
43	Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular <i>Mycobacterium avium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1728-1733.	1.4	57
44	Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1115-1123.	1.3	57
45	The pyrazinamide susceptibility breakpoint above which combination therapy fails. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2420-2425.	1.3	56
46	Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. <i>Science Advances</i> , 2017, 3, e1701102.	4.7	56
47	Tigecycline Is Highly Efficacious against <i>Mycobacterium abscessus</i> Pulmonary Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2895-2900.	1.4	54
48	Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. <i>Clinical Infectious Diseases</i> , 2018, 67, S327-S335.	2.9	53
49	The Crisis of Resistance: Identifying Drug Exposures to Suppress Amplification of Resistant Mutant Subpopulations. <i>Clinical Infectious Diseases</i> , 2006, 42, 525-532.	2.9	51
50	Redefining Multidrug-Resistant Tuberculosis Based on Clinical Response to Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6111-6115.	1.4	51
51	Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary <i>Mycobacterium avium</i> intracellular complex disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i3-i19.	1.3	51
52	Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5107-5112.	1.4	47
53	Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-Fourths. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2259-2264.	1.4	47
54	Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated <i>Mycobacterium avium</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2534-2539.	1.4	46

#	ARTICLE	IF	CITATIONS
55	<scp>d</scp>-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. <i>Clinical Infectious Diseases</i> , 2018, 67, S308-S316.	2.9	45
56	Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant <i>Mycobacterium tuberculosis</i> but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5085-5089.	1.4	44
57	Thioridazine Pharmacokinetic-Pharmacodynamic Parameters “Wobble” during Treatment of Tuberculosis: a Theoretical Basis for Shorter-Duration Curative Monotherapy with Congeners. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5870-5877.	1.4	42
58	Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary <i>Mycobacterium abscessus</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6374-6376.	1.4	41
59	Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber <i>Mycobacterium abscessus</i> Disease Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1242-1248.	1.4	41
60	A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. <i>Clinical Infectious Diseases</i> , 2016, 63, S95-S101.	2.9	40
61	A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies. <i>EBioMedicine</i> , 2016, 6, 126-138.	2.7	40
62	Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1350-1359.	2.9	40
63	Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps. <i>Clinical Infectious Diseases</i> , 2016, 63, S80-S87.	2.9	39
64	Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. <i>Nature Medicine</i> , 2020, 26, 1435-1443.	15.2	38
65	Meningeal Tuberculosis. <i>Medicine (United States)</i> , 2010, 89, 189-195.	0.4	37
66	Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5928-5932.	1.4	37
67	Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo. <i>Clinical Infectious Diseases</i> , 2016, 63, S88-S94.	2.9	37
68	In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens. <i>Current Pharmaceutical Design</i> , 2011, 17, 2881-2888.	0.9	36
69	Repurposing drugs for treatment of <i>Mycobacterium abscessus</i> : a view to a kill. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1212-1217.	1.3	36
70	Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 587-591.	1.3	34
71	Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. <i>Clinical Infectious Diseases</i> , 2016, 63, S102-S109.	2.9	34
72	Tedizolid is highly bactericidal in the treatment of pulmonary <i>Mycobacterium avium</i> complex disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i30-i35.	1.3	34

#	ARTICLE	IF	CITATIONS
73	Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality. <i>EBioMedicine</i> , 2015, 2, 1634-1639.	2.7	33
74	Ethambutol Pharmacokinetic Variability Is Linked to Body Mass in Overweight, Obese, and Extremely Obese People. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1502-1507.	1.4	31
75	Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5922-5927.	1.4	31
76	Biological variability and the emergence of multidrug-resistant tuberculosis. <i>Nature Genetics</i> , 2013, 45, 720-721.	9.4	30
77	The discovery of ceftazidime/avibactam as an anti- <i>Mycobacterium avium</i> agent. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i36-i42.	1.3	29
78	Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S317-S326.	2.9	29
79	Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	29
80	A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live <i>Bacillus Calmette-Guérin</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1277-1291.	2.5	28
81	<i>In Silico</i> Children and the Glass Mouse Model: Clinical Trial Simulations To Identify and Individualize Optimal Isoniazid Doses in Children with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 539-545.	1.4	27
82	Thioridazine as Chemotherapy for <i>Mycobacterium avium</i> Complex Diseases. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4652-4658.	1.4	27
83	Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 370-380.	2.5	27
84	Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. <i>EBioMedicine</i> , 2015, 2, 1640-1649.	2.7	26
85	Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary <i>Mycobacterium avium</i> Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2157-2163.	1.4	26
86	Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. <i>Clinical Infectious Diseases</i> , 2018, 67, S349-S358.	2.9	26
87	Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs. <i>Clinical Infectious Diseases</i> , 2018, 67, S267-S273.	2.9	26
88	The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S336-S341.	2.9	26
89	Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of <i>Mycobacterium abscessus</i> Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3779-3785.	1.4	25
90	Linezolid as treatment for pulmonary <i>Mycobacterium avium</i> disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i24-i29.	1.3	25

#	ARTICLE	IF	CITATIONS
91	A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i48-i53.	1.3	25
92	Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2014, 14, 115.	1.3	24
93	Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3193-3195.	1.4	23
94	Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	23
95	Gatifloxacin Pharmacokinetics/Pharmacodynamicsâ€‘based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S274-S283.	2.9	23
96	Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2273-2279.	1.4	21
97	Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. <i>International Journal of Infectious Diseases</i> , 2021, 105, 688-694.	1.5	20
98	New Susceptibility Breakpoints and the Regional Variability of MIC Distribution in Mycobacterium tuberculosis Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5428-5428.	1.4	19
99	Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 801-811.	1.1	19
100	Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. <i>Clinical Infectious Diseases</i> , 2018, 67, 1743-1749.	2.9	19
101	Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S342-S348.	2.9	18
102	Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis. <i>Journal of Infectious Diseases</i> , 2019, 219, 975-985.	1.9	18
103	Acquired Drug Resistance: We Can Do More Than We Think!. <i>Clinical Infectious Diseases</i> , 2015, 60, 969-970.	2.9	17
104	The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism. <i>EBioMedicine</i> , 2016, 11, 118-126.	2.7	17
105	Pan-tuberculosis regimens: an argument against. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 240-242.	5.2	17
106	Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!. <i>Clinical Infectious Diseases</i> , 2018, 67, S359-S364.	2.9	17
107	Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 545-552.	0.8	16
108	Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!. <i>Clinical Infectious Diseases</i> , 2015, 61, S635-S642.	2.9	16

#	ARTICLE	IF	CITATIONS
109	Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, S284-S292.	2.9	16
110	Anidulafungin in the treatment of invasive fungal infections. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 71-78.	0.9	15
111	Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment. <i>International Journal of Infectious Diseases</i> , 2018, 68, 18-23.	1.5	15
112	Clofazimine for the Treatment of <i>Mycobacterium kansasii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	15
113	Minocycline treatment for pulmonary <i>Mycobacterium avium</i> complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1952-1961.	1.3	15
114	Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1115-1120.	1.4	14
115	A "shock and awe" thioridazine and moxifloxacin combination-based regimen for pulmonary <i>Mycobacterium avium</i> intracellular complex disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i43-i47.	1.3	14
116	Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 392-399.	1.3	14
117	Clinicopathological features of cutaneous histoplasmosis in human immunodeficiency virus-infected patients in Zimbabwe. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2001, 95, 635-636.	0.7	13
118	Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. <i>BMC Infectious Diseases</i> , 2016, 16, 242.	1.3	13
119	A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground. <i>Clinical Infectious Diseases</i> , 2016, 63, S75-S79.	2.9	13
120	Once-a-week tigecycline for the treatment of drug-resistant TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1607-1617.	1.3	13
121	Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	13
122	Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	13
123	<i>Mycobacterium</i> Shuttle Vectors Designed for High-Level Protein Expression in Infected Macrophages. <i>Applied and Environmental Microbiology</i> , 2012, 78, 6829-6837.	1.4	12
124	Cefdinir and Î²-Lactamase Inhibitor Independent Efficacy Against <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Pharmacology</i> , 2021, 12, 677005.	1.6	12
125	Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. <i>PLoS ONE</i> , 2017, 12, e0187624.	1.1	12
126	Late Complications of <i>Candida (Torulopsis) glabrata</i> Fungemia: Description of a Phenomenon. <i>Scandinavian Journal of Infectious Diseases</i> , 2002, 34, 817-818.	1.5	11

#	ARTICLE	IF	CITATIONS
127	A programme to create short-course chemotherapy for pulmonary <i>Mycobacterium avium</i> disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i54-i60.	1.3	11
128	Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary <i>Mycobacterium avium</i> infection is due to acquired resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i20-i23.	1.3	11
129	Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse. <i>Communications Biology</i> , 2021, 4, 664.	2.0	11
130	Omadacycline efficacy in the hollow fibre system model of pulmonary <i>Mycobacterium avium</i> complex and potency at clinically attainable doses. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1694-1705.	1.3	11
131	Pharmacokinetic/pharmacodynamic-based treatment of disseminated <i>Mycobacterium avium</i> . <i>Future Microbiology</i> , 2011, 6, 433-439.	1.0	10
132	Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 1092-1100.	1.1	10
133	Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 898.	4.6	9
134	Comparison of Rifamycins for Efficacy Against <i>Mycobacterium avium</i> Complex and Resistance Emergence in the Hollow Fiber Model System. <i>Frontiers in Pharmacology</i> , 2021, 12, 645264.	1.6	9
135	Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary <i>Mycobacterium kansasii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8
136	Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Pharmacology</i> , 2020, 11, 616294.	1.6	8
137	Reply to Wallis et al. and Mitchison et al.. <i>Journal of Infectious Diseases</i> , 2007, 195, 1872-1873.	1.9	7
138	Acquired Drug Resistance Because of Pharmacokinetic Variability in a Young Child With Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1205.	1.1	7
139	Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, <i>Sui Generis: The Road Ahead</i> . <i>Clinical Infectious Diseases</i> , 2016, 63, S110-S115.	2.9	7
140	Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis. <i>International Journal of Audiology</i> , 2020, 59, 219-223.	0.9	7
141	<i>Mycobacterium tuberculosis</i> sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration. <i>International Journal of Infectious Diseases</i> , 2021, 104, 680-684.	1.5	7
142	Potency of vancomycin against <i>Mycobacterium tuberculosis</i> in the hollow fiber system model. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 403-410.	0.9	7
143	Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2020-2027.	1.3	6
144	Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2994-3002.	1.3	6

#	ARTICLE	IF	CITATIONS
145	Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	6
146	Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy. Current Opinion in Drug Discovery & Development, 2008, 11, 32-42.	1.9	6
147	Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. Journal of Antimicrobial Chemotherapy, 2015, 70, 320-321.	1.3	5
148	pH Conditions under Which Pyrazinamide Works in Humans. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	5
149	Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis. Frontiers in Pharmacology, 2021, 12, 776969.	1.6	5
150	Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 706-707.	0.6	4
151	Reply to Raoult. Clinical Infectious Diseases, 2017, 64, 984-984.	2.9	4
152	Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?. Clinical Infectious Diseases, 2018, 67, 717-718.	2.9	4
153	The Relationship Between Drug Concentration in Tuberculosis Lesions, Epithelial Lining Fluid, and Clinical Outcomes. Clinical Infectious Diseases, 2021, 73, e3374-e3376.	2.9	4
154	Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, e0027821.	1.4	4
155	Quantitative assessment of the activity of antituberculosis drugs and regimens. Expert Review of Anti-Infective Therapy, 2019, 17, 449-457.	2.0	3
156	sncRNA-1 Is a Small Noncoding RNA Produced by Mycobacterium tuberculosis in Infected Cells That Positively Regulates Genes Coupled to Oleic Acid Biosynthesis. Frontiers in Microbiology, 2020, 11, 1631.	1.5	3
157	Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection. Antimicrobial Agents and Chemotherapy, 2022, 66, e0232021.	1.4	3
158	Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 0, , .	1.3	3
159	Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis. Journal of Infectious Diseases, 2015, 212, 166-167.	1.9	2
160	Glucan Synthase Inhibitors. Infectious Disease and Therapy, 2007, , 355-378.	0.0	2
161	Drug Concentration Monitoring in Mycobacterium avium Lung Disease: Problems with Methods and Conclusions. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 554-555.	2.5	1
162	An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease. Journal of Global Antimicrobial Resistance, 2022, 28, 71-77.	0.9	1

#	ARTICLE	IF	CITATIONS
163	Reply to "Pharmacokinetic Mismatch of Tuberculosis Drugs", Antimicrobial Agents and Chemotherapy, 2012, 56, 1667-1667.	1.4	0
164	Reply to "Breakpoints and Drug Exposure Are Inevitably Closely Linked", Antimicrobial Agents and Chemotherapy, 2015, 59, 1385-1385.	1.4	0
165	Reply to Zimenkov, "Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance", Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	0
166	Dosing tuberculosis drugs in young children: the road ahead. The Lancet Child and Adolescent Health, 2019, 3, 590-592.	2.7	0
167	Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. IJC Heart and Vasculature, 2019, 22, 105-110.	0.6	0
168	Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis. European Respiratory Journal, 2021, 57, 2004454.	3.1	0